INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 415m ago
HOUSE PTR15m ago
SEC 13F14m ago
ROBINHOOD CHAIN14m ago
SEC FORM 4/Grant or awardVerified data

Skvarka Jan reported ZNTL

Director · Zentalis Pharmaceuticals, Inc. · Common Stock

Side
A
Value
—
Shares
57.1K
Price
—
Executed
Jun 16, 2026
Disclosed
Jun 18, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 16 executedJun 18, 2026 disclosed

ZNTL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 27.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ZNTL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    KE
    Kariuki EnochDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    57.1K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Johnson David MichaelDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    57.1K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CS
    Campbell ShannonDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    114.2K sh
    		May 26, 2026May 27, 2026
    traded May 26, 2026
    		+1dSEC FORM 4

    Evidence

    1
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    6,894 sh
    		Feb 10, 2026Feb 10, 2026
    traded Feb 10, 2026
    		+0dSEC FORM 4

    Evidence

    1
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$8,086
    3,379 sh
    		Feb 9, 2026Feb 10, 2026
    traded Feb 9, 2026
    		+1dSEC FORM 4

    Evidence

    8
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$73K
    30.0K sh
    		Feb 6, 2026Feb 10, 2026
    traded Feb 6, 2026
    		+4dSEC FORM 4

    Evidence

    5
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6,477
    2,540 sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,398
    556 sh
    		Feb 3, 2026Feb 4, 2026
    traded Feb 3, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BB
    Bucher James BChief Legal Officer
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BI
    Bruns IngmarChief Medical Officer
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    365.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    9
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001838042-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 16, 2026
    Published
    Jun 18, 2026
    Ingested by INSIDER
    Nov 5, 03:52 UTC
    Last re-read
    Nov 5, 03:52 UTC

    Extracted facts

    Filer
    Skvarka Jan
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Zentalis Pharmaceuticals, Inc.
    Ticker
    ZNTL
    Shares
    57.1K
    Price per share
    $0
    Execution date (reported)
    Jun 16, 2026
    Owned after transaction
    264.3K shares
    Days from execution to publication
    2

    What this establishes

    Skvarka Jan filed this Form 4 reporting a grant or award of ZNTL on Jun 16, 2026. It became public on Jun 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Skvarka Jancik:0001838042
    Issuer
    Zentalis Pharmaceuticals, Inc.cik:0001725160

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.